Why the study?
AF carries stroke and silent cerebral emboli risks related to LA remodeling and activation of inflammatory and coagulation systems; the effects of cardioversion and short-lasting AF on these factors remain to be explored.
Does electrical cardioversion improve left atrial hemodynamics and reduce inflammatory and coagulative biomarkers in anticoagulant-naïve patients with recent-onset atrial fibrillation?
Does electrical cardioversion improve left atrial hemodynamics and reduce inflammatory and coagulative biomarkers in anticoagulant-naïve patients with recent-onset atrial fibrillation?
Electrical cardioversion for recent-onset atrial fibrillation resolves left atrial stunning and reduces thrombogenic biomarkers within 10 days, though functional recovery is blunted in patients with a prior history of AF.
Supports prompt LA recovery post-cardioversion in recent-onset AF; leaves open differential recovery and thrombotic risk by prior AF history.
PURPOSE: Atrial fibrillation (AF) imposes an inherent risk for stroke and silent cerebral emboli, partly related to left atrial (LA) remodeling and activation of inflammatory and coagulation systems. The aim was to explore the effects of cardioversion (CV) and short-lasting AF on left atrial hemodynamics, inflammatory, coagulative and cardiac biomarkers, and the association between LA functional recovery and the presence of a prior history of AF. METHODS: Patients referred for CV within 48 h after AF onset were prospectively included. Echocardiography and blood sampling were performed immediately prior, 1-3 h after, and at 7-10 days after CV. The presence of chronic white matter hyperintensities (WMH) on magnetic resonance imaging was related to biomarker levels. The LA emptying fraction (LAEF), LA peak longitudinal strain during reservoir, conduit, and contractile phases improved significantly after CV. Only LAEF normalized within 10 days. Interleukin-6, high-sensitivity cardiac-troponin-T (hs-cTNT), N-terminal-pro-brain-natriuretic peptide, prothrombin-fragment 1+2 (PTf1+2), and fibrinogen decreased significantly after CV. There was a trend towards higher C-reactive protein, hs-cTNT, and PTf1+2 levels in patients with WMH (n=21) compared to those without (n=22). At 7-10 days, the LAEF was significantly lower in patients with a prior history of AF versus those without. CONCLUSION: Although LA stunning resolved within 10 days, LAEF remained significantly lower in patients with a prior history of AF versus those without. Inflammatory and coagulative biomarkers were higher before CV, but subsided after 7-10 days, which altogether might suggest an enhanced thrombogenicity, even in these low-risk patients.
No takes yet. Share an insight, caveat, or question.
Arvanitis et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: